Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer

被引:0
作者
Chen, Chengcong [1 ]
Feng, Yan Summer [2 ]
Wang, Ziyi [1 ]
Gupta, Manish [2 ]
Xu, Xu Steven [2 ]
Yan, Xiaoyu [1 ]
机构
[1] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, Hong Kong, Peoples R China
[2] Genmab Inc, Clin Pharmacol & Quantitat Sci, Princeton, NJ 08536 USA
关键词
Tumor growth inhibition model; Tumor growth rate; Liver metastasis; Metastatic colorectal cancer; SIZE;
D O I
10.1016/j.ejca.2024.114147
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We aim to compare the prognostic value of organ-specific dynamics with the sum of the longest diameter (SLD) dynamics in patients with metastatic colorectal cancer (mCRC). Methods: All datasets are accessible in Project Data Sphere, an open-access platform. The tumor growth inhibition models developed based on organ-level SLD and SLD were used to estimate the organ-specific tumor growth rates (KGs) and SLD KG. The early tumor shrinkage (ETS) from baseline to the first measurement after treatment was also evaluated. The relationship between organ-specific dynamics, SLD dynamics, and survival outcomes (overall survival, OS; progression-free survival, PFS) was quantified using Kaplan-Meier analysis and Cox regression. Results: This study included 3687 patients from 6 phase III mCRC trials. The liver emerged as the most frequent metastatic site (2901, 78.7 %), with variable KGs across different organs in individual patients (liver 0.0243 > lung 0.0202 > lymph node 0.0127 > other 0.0118 [week(-1)]). Notably, the dynamics for different organs did not equally contribute to predicting survival outcomes. In liver metastasis cases, liver KG proved to be a superior prognostic indicator for OS and surpasses the predictive performance of SLD, (C-index, liver KG 0.610 vs SLD KG 0.606). A similar result can be found for PFS. Moreover, liver ETS also outperforms SLD ETS in predicting survival. Cox regression analysis confirmed liver KG is the most significant variable in survival prediction. Conclusions: In mCRC patients with liver metastasis, liver dynamics is the primary prognostic indicator for both PFS and OS. In future drug development for mCRC, greater emphasis should be directed towards understanding the dynamics of liver metastasis development.
引用
收藏
页数:7
相关论文
共 23 条
[1]   Novel patterns of response under immunotherapy [J].
Borcoman, E. ;
Kanjanapan, Y. ;
Champiat, S. ;
Kato, S. ;
Servois, V. ;
Kurzrock, R. ;
Goel, S. ;
Bedard, P. ;
Le Tourneau, C. .
ANNALS OF ONCOLOGY, 2019, 30 (03) :385-396
[2]   Understanding of interaction (subgroup) analysis in clinical trials [J].
Brankovic, Milos ;
Kardys, Isabella ;
Steyerberg, Ewout W. ;
Lemeshow, Stanley ;
Markovic, Maw ;
Rizopoulos, Dimitris ;
Boersma, Eric .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2019, 49 (08)
[3]   Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models [J].
Bruno, Rene ;
Bottino, Dean ;
de Alwis, Dinesh P. ;
Fojo, Antonio T. ;
Guedj, Jeremie ;
Liu, Chao ;
Swanson, Kristin R. ;
Zheng, Jenny ;
Zheng, Yanan ;
Jin, Jin Y. .
CLINICAL CANCER RESEARCH, 2020, 26 (08) :1787-1795
[4]   Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study [J].
Claret, Laurent ;
Pentafragka, Christina ;
Karovic, Sanja ;
Zhao, Binsheng ;
Schwartz, Lawrence H. ;
Maitland, Michael L. ;
Bruno, Rene .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) :49-54
[5]   Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics [J].
Claret, Laurent ;
Girard, Pascal ;
Hoff, Paulo M. ;
Van Cutsem, Eric ;
Zuideveld, Klaas P. ;
Jorga, Karin ;
Fagerberg, Jan ;
Bruno, Rene .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) :4103-4108
[6]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[7]   Baseline tumour measurements predict survival in advanced non-small cell lung cancer [J].
Gerber, D. E. ;
Dahlberg, S. E. ;
Sandler, A. B. ;
Ahn, D. H. ;
Schiller, J. H. ;
Brahmer, J. R. ;
Johnson, D. H. .
BRITISH JOURNAL OF CANCER, 2013, 109 (06) :1476-1481
[8]   Pattern of metastasis and outcome in patients with breast cancer [J].
Gerratana, L. ;
Fanotto, V. ;
Bonotto, M. ;
Bolzonello, S. ;
Minisini, A. M. ;
Fasola, G. ;
Puglisi, F. .
CLINICAL & EXPERIMENTAL METASTASIS, 2015, 32 (02) :125-133
[9]   Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy [J].
Kerioui, M. ;
Desmee, S. ;
Mercier, F. ;
Lin, A. ;
Wu, B. ;
Jin, J. Y. ;
Shen, X. ;
Le Tourneau, C. ;
Bruno, R. ;
Guedj, J. .
ESMO OPEN, 2022, 7 (01)
[10]   Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel [J].
Krishnan, Sreenath M. ;
Laarif, Sofiene S. ;
Bender, Brendan C. ;
Quartino, Angelica L. ;
Friberg, Lena E. .
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (05) :511-521